Abstract:

Estrogen-like drugs are efficient for prevention and treatment of osteoporosis. In order to improve absorptivity and bioavailability for estrogen-like drugs in human body, enhance affinity between estrogen-like drugs and skeletal system, and reduce adverse reactions due to long term administration, new improvements in estrogen-like drugs have been made in terms of drug targeting and drug synthesis in recent years. Estrogen controlled release nano-carriers and some small peptide, tetracycline and RGD-peptide bone-targeting drugs are widely used, which provide novel methods and ideas for osteoporosis treatment. In this paper, research progresses of estrogen-like drugs are reviewed.

Key words: osteoporosis, estrogen, nanocarrier, bonetargeting